Cape Hematology and Bone Marrow Transplant Unit

Cape Town, South Africa

Cape Hematology and Bone Marrow Transplant Unit

Cape Town, South Africa
SEARCH FILTERS
Time filter
Source Type

Basak G.W.,Medical University of Warsaw | De Wreede L.C.,Leiden University | Van Biezen A.,Leiden University | Wiktor-Jedrzejczak W.,Medical University of Warsaw | And 15 more authors.
Bone Marrow Transplantation | Year: 2013

Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT (N=168) or BMT (N=216) and were treated with donor lymphocyte infusions (DLI). Univariate analysis revealed a lower probability of OS after DLI in patients relapsing after PBSCT vs BMT (66% vs 79% at 5 years, P=0.013). However, a multivariate Cox analysis did not reveal any significant impact of PBSCT as a risk factor for decreased OS for patients transplanted in first chronic phase (CP1; hazard ratio (HR) 1.036, 95% confidence interval (CI) 0.619-1.734). A statistical interaction term suggested that the impact of stem cell source on OS after DLI was different for those transplanted in advanced phases (negative impact of previous PBSCT-HR 2.176, 95% CI 0.930-5.091). In summary, the stem cell source does not affect the OS of CML patients who underwent PBSCT in CP1, relapsed and were treated with DLI. However, when the patients were transplanted in advanced phases, previous PBSCT seems to negatively affect OS after DLI compared with BMT. © 2013 Macmillan Publishers Limited All rights reserved.

Loading Cape Hematology and Bone Marrow Transplant Unit collaborators
Loading Cape Hematology and Bone Marrow Transplant Unit collaborators